Compare INTT & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTT | JSPR |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | United States | United States |
| Employees | 407 | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.4M | 26.3M |
| IPO Year | 1997 | 2019 |
| Metric | INTT | JSPR |
|---|---|---|
| Price | $11.57 | $0.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $13.50 | ★ $15.50 |
| AVG Volume (30 Days) | 98.4K | ★ 340.5K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.22 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $66,801,000.00 | N/A |
| Revenue This Year | $15.82 | N/A |
| Revenue Next Year | $9.10 | N/A |
| P/E Ratio | $194.33 | ★ N/A |
| Revenue Growth | ★ 66.06 | N/A |
| 52 Week Low | $7.07 | $0.32 |
| 52 Week High | $20.00 | $2.69 |
| Indicator | INTT | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 50.38 | 44.49 |
| Support Level | $11.17 | $0.56 |
| Resistance Level | $11.83 | $1.01 |
| Average True Range (ATR) | 0.47 | 0.05 |
| MACD | 0.19 | -0.01 |
| Stochastic Oscillator | 80.00 | 34.44 |
inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.